A Health Economic Evaluation of the Impact of Pathogen Reduction Technology on Emerging Pathogens within the Platelet Collection and Transfusion Space
Author(s)
Dierick K1, Sweerts L2, Lee Y3, Cardoso M4
1Terumo BCT Europe NV, Zavemtem, Belgium, 2Terumo BCT, Alkmaar, Netherlands, 3Terumo BCT Asia, SINGAPORE, 01, Singapore, 4Terumo BCT, Zaventem, Belgium
OBJECTIVES Given the recent COVID-19 outbreak our objective was to assess the role a European installed base of pathogen reduction technology (PRT) could have on controlling the potential devastating impact of future bloodborne emerging pathogens. In specific we wanted to assess its impact within the platelets collection and transfusion environment. METHODS Based on literature review, the characteristics of common bloodborne pathogens (e.g. the basic reproduction number, mortality and morbidity), current blood testing (BT) capabilities (e.g. blood test availability and sensitivity), pathogen reduction levels (e.g. log kill rate) as well as cost information in case of infection, were identified and modelled to assess the potential scenarios from a direct and indirect costs point of view. The assessment was performed for platelets collected within the current EU countries. RESULTS Assuming 2 million platelet collections and in case a new pathogen emerges for which no sensitive BT is immediately available. PRT could, within the first wave of infections, prevent 3696 infections through blood transfusion and avoid 2634 infections from transfused patients to others. Avoiding these infections would reduce health care expenditures by 97 million euro and save 25.000 days of hospitalization. Up to 1500 lives would be saved which would have an immediate positive economic impact of 74 million euro. Indirectly PRT would save 46189 days of productivity and reduce overall indirect morbidity costs by 19,6 million euro. CONCLUSIONS In case of an emerging pathogen for which no highly sensitive DT is directly available, PRT and its known ability to avoid transfusion transmitted infections in platelets, may facilitate substantial economic and societal savings. As we only investigated for platelets, future research that considers plasma collections or red blood cell collections may be relevant. Country differences as well as differences based on the procedure to collect platelets may occur.
Conference/Value in Health Info
2020-11, ISPOR Europe 2020, Milan, Italy
Value in Health, Volume 23, Issue S2 (December 2020)
Code
PMD13
Topic
Economic Evaluation, Epidemiology & Public Health, Medical Technologies
Topic Subcategory
Budget Impact Analysis, Medical Devices, Public Health
Disease
Infectious Disease (non-vaccine), Medical Devices